Definitive Contract HHSN261201000102C

<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a $1,416,758.40 Cost Plus Fixed Fee contract to Sensopath Technologies, Inc., a Woman Owned Small Business, for a Small Business Innovation Research (SBIR) Program Phase II action. The contract, which has a total small business set aside, was awarded on September 28, 2012 with an ultimate completion date of May 22, 2015. The contract delivers research and development services under the SBIR program.</p>

This is a $182,050 firm fixed price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nanoivd, Inc., a small disadvantaged, woman-owned business. The contract is for TAS::75 0849::TAS and has a total small business set-aside designation. The period of performance runs from the award date of September 30, 2010 through the ultimate completion date of March 30, 2011. Nanoivd, Inc. is the prime contractor, and no subcontractors are mentioned. The contract...

<p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nanospectra Biosciences, Inc. for &quot;Targeted Photothermal Ablation of Melanoma&quot;. The contract has a firm fixed price ceiling of $200,000.00 and a period of performance ending on September 23, 2011. As an SBIR Phase I award, this contract is focused on feasibility research and development of the proposed technology.</p>

This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...

This is a Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to Tetraimaging LLC, a self-certified small disadvantaged business. The contract, valued at $1,999,930.00, is for the development of a multilayer strip ion chamber device to measure flash-RT beams under the SBIR (Small Business Innovation Research) Program Phase II. The period of performance is from September 16, 2024, to September 15, 2026, and the contract has a total small...

This is a $247,568 Firm Fixed Price contract awarded by the National Cancer Institute (NCI) to Cellsight Technologies, Inc., a woman-owned small business. The contract is for research and development related to a novel PET imaging agent, [18F]F-ARAG, to assess response to cancer immunotherapies. This contract is part of NCI's Small Business Innovation Research (SBIR) program, which sets aside certain research and development contracts for small businesses. Cellsight Technologies has also...

<p>This is a $1,908,932.02 Firm Fixed Price Definitive Contract awarded by the National Institutes of Health (NIH) National Cancer Institute to Photolitec LLC, a small business limited liability company, for SBIR Phase II research on image-guided photodynamic therapy in combination with chemotherapy for lung cancer treatment. The contract was set aside for Total Small Business and has a completion date of February 18, 2022.</p>

<p>This is a $249,330.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to ITI Health, Inc. (doing business as Zielbio) for a Small Business Innovation Research (SBIR) Phase I project on novel imaging agents to expand the clinical toolkit for cancer diagnosis, staging, and treatment. The contract was awarded on September 30, 2011 with a completion date of December 5, 2013. This award is designated as a Total Small Business set-aside contract.</p>

This is a $299,640.99 Firm Fixed Price contract awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to Cellsight Technologies, Inc. The contract is for research and development services related to a noninvasive PET imaging strategy for longitudinal monitoring of the tumor microenvironment, under the Small Business Innovation Research (SBIR) program. The contract was set aside for small business participation. Cellsight Technologies, Inc....

<p>This is a $2,300,000.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Cancer Targeted Technology LLC, a small business located in Pullman, Washington. The contract is for the development of an innovative Prostate-Specific Membrane Antigen (PSMA)-targeted radionuclide therapy for prostate cancer. The contract has a completion date of August 29, 2018. This award represents a set-aside for small businesses.</p>